{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:54Z","timestamp":1772165694457,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T00:00:00Z","timestamp":1617840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Decreased erythropoietin levels and impaired iron metabolism due to excessive hepcidin levels are responsible for renal anaemia in patients undergoing haemodialysis. Recently, erythroferrone (ERFE) has been identified as a factor that regulates hepcidin. In addition, fibroblast growth factor 23 (FGF23), which has been recognized as a phosphorus-regulating hormone, appears to be involved in haematopoietic regulation. Clarification of the detailed mechanism of haematopoiesis could lead to the improvement of renal anaemia treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Epoetin beta pegol (CERA) was administered to patients undergoing haemodialysis at week 0, and the same amount of CERA with saccharated ferric oxide (SFO) was administered at week 4. The changes in haematopoiesis-related biomarkers, including ERFE, intact FGF23 (iFGF23), C-terminal FGF23 (cFGF23), and inflammatory markers, were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Administration of CERA increased ERFE levels, decreased hepcidin levels, and stimulated iron usage for haematopoiesis, leading to an increase in reticulocytes (Ret) and haemoglobin (Hb). Simultaneous administration of SFO with CERA (CERA + SFO) significantly attenuated the responses of ERFE, Ret, and Hb compared with CERA alone. Although iFGF23 levels were not affected by either CERA or CERA + SFO, cFGF23 was significantly elevated from baseline after CERA. Since cFGF23 levels were not affected by CERA + SFO, cFGF23 levels after CERA + SFO were significantly lower than those after CERA alone. The ratio of iFGF23 to cFGF23 (i\/cFGF23 ratio) was significantly higher after CERA + SFO than that after CERA alone. In addition, high-sensitivity C-reactive protein (hsCRP) levels were significantly higher after CERA + SFO than after CERA alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Administration of SFO suppressed haematopoietic responses induced by CERA. Elevation of i\/cFGF23 ratio and hsCRP could account for the inhibitory effects of SFO on haematopoiesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      This study was registered with the University Hospital Medical Information Network (ID\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr_view.cgi?recptno=R000018835\">UMIN000016552<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-021-02320-2","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T10:03:19Z","timestamp":1617876199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Saccharated ferric oxide attenuates haematopoietic response induced by epoetin beta pegol in patients undergoing haemodialysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Takahide","family":"Iwasaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shioko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuto","family":"Hanawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Hasuike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kuragano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"key":"2320_CR1","doi-asserted-by":"publisher","unstructured":"Nakanishi T, Kuragano T. Potential hazards of recent trends in liberal iron use for renal anemia. Clin Kidney J. 2020;14(1):59-69. https:\/\/doi.org\/10.1093\/ckj\/sfaa117. eCollection 2021 Jan.","DOI":"10.1093\/ckj\/sfaa117"},{"issue":"4","key":"2320_CR2","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1152\/physrev.00008.2013","volume":"93","author":"T Ganz","year":"2013","unstructured":"Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93(4):1721\u201341. https:\/\/doi.org\/10.1152\/physrev.00008.2013.","journal-title":"Physiol Rev"},{"issue":"2","key":"2320_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41581-019-0197-5","volume":"16","author":"RPL van Swelm","year":"2020","unstructured":"van Swelm RPL, Wetzels JFM, Swinkels DW. The multifaceted role of iron in renal health and disease. Nat Rev Nephrol. 2020;16(2):77\u201398. https:\/\/doi.org\/10.1038\/s41581-019-0197-5.","journal-title":"Nat Rev Nephrol"},{"key":"2320_CR4","doi-asserted-by":"publisher","unstructured":"Akchurin O, Sureshbabu A, Doty SB, Zhu YS, Patino E, Cunningham-Rundles S, et al. Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease. Am J Physiol Ren Physiol. 2016;311(5):F877\u201389. https:\/\/doi.org\/10.1152\/ajprenal.00089.2016.","DOI":"10.1152\/ajprenal.00089.2016"},{"key":"2320_CR5","doi-asserted-by":"publisher","unstructured":"Khorramian E, Fung E, Chua K, Gabayan V, Ganz T, Nemeth E, et al. In a mouse model of sepsis, hepcidin ablation ameliorates anemia more effectively than iron and erythropoietin treatment. Shock. 2017;48(4):490\u20137. https:\/\/doi.org\/10.1097\/SHK.0000000000000886.","DOI":"10.1097\/SHK.0000000000000886"},{"issue":"January","key":"2320_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clinbiochem.2020.02.001","volume":"79","author":"S Appleby","year":"2020","unstructured":"Appleby S, Chew-Harris J, Troughton RW, Richards AM, Pemberton CJ. Analytical and biological assessment of circulating human erythroferrone. Clin Biochem. 2020;79(January):41\u20137. https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.02.001.","journal-title":"Clin Biochem"},{"issue":"7","key":"2320_CR7","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/ng.2996","volume":"46","author":"L Kautz","year":"2014","unstructured":"Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678\u201384. https:\/\/doi.org\/10.1038\/ng.2996.","journal-title":"Nat Genet"},{"issue":"3","key":"2320_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0151601","volume":"11","author":"H Honda","year":"2016","unstructured":"Honda H, Kobayashi Y, Onuma S, Shibagaki K, Yuza T, Hirao K, et al. Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis. PLoS One. 2016;11(3):1\u201310.","journal-title":"PLoS One"},{"key":"2320_CR9","first-page":"12(10)","volume":"1","author":"I Flamme","year":"2017","unstructured":"Flamme I, Ellinghaus P, Urrego D, Kr\u00fcger T. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase. PLoS One. 2017;1:12(10).","journal-title":"PLoS One"},{"key":"2320_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1152\/physrev.00002.2011","volume":"92","author":"A Martin","year":"2012","unstructured":"Martin A, David V, Quarles LD. Regulation and function of the FGF23\/klotho endocrine pathways. Physiol Rev. 2012;92:131\u201355.","journal-title":"Physiol Rev"},{"key":"2320_CR11","doi-asserted-by":"publisher","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393\u2013408. https:\/\/doi.org\/10.1172\/JCI46122.","DOI":"10.1172\/JCI46122"},{"issue":"9","key":"2320_CR12","first-page":"1448","volume":"32","author":"J Rossaint","year":"2017","unstructured":"Rossaint J, Unruh M, Zarbock A. Fibroblast growth factor 23 actions in inflammation: a key factor in CKD outcomes. Nephrol Dial Transplant. 2017;32(9):1448\u201353.","journal-title":"Nephrol Dial Transplant"},{"key":"2320_CR13","doi-asserted-by":"publisher","unstructured":"Almroth G, L\u00f6nn J, Uhlin F, Nayeri F, Brudin L, Andersson B, et al. Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high-sensitivity C-reactive protein and soluble urokinase plasminogen activator receptor. Inflammation markers in chronic haemodialysis patients? Scand J Immunol. 2013;78(3):285\u201390. https:\/\/doi.org\/10.1111\/sji.12082.","DOI":"10.1111\/sji.12082"},{"issue":"14","key":"2320_CR14","doi-asserted-by":"publisher","first-page":"9795","DOI":"10.1074\/jbc.M113.527150","volume":"289","author":"LM Coe","year":"2014","unstructured":"Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem. 2014;289(14):9795\u2013810. https:\/\/doi.org\/10.1074\/jbc.M113.527150.","journal-title":"J Biol Chem"},{"key":"2320_CR15","doi-asserted-by":"publisher","unstructured":"David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016;89(1):135\u201346. https:\/\/doi.org\/10.1038\/ki.2015.290.","DOI":"10.1038\/ki.2015.290"},{"key":"2320_CR16","first-page":"411","volume-title":"Coupling fibroblast growth factor 23 production and cleavage: Iron deficiency, rickets, and kidney disease. Vol. 23, Current Opinion in Nephrology and Hypertension","author":"M Wolf","year":"2014","unstructured":"Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: Iron deficiency, rickets, and kidney disease. Vol. 23, Current Opinion in Nephrology and Hypertension: Lippincott Williams and Wilkins; 2014. p. 411\u20139."},{"key":"2320_CR17","doi-asserted-by":"publisher","unstructured":"Agoro R, Park MY, Le Henaff C, Jankauskas S, Gaias A, Chen G, Mohammadi M, Sitara D. C-FGF23 peptide alleviates hypoferremia during acute inflammation. Haematologica. 2021;106(2):391-403. https:\/\/doi.org\/10.3324\/haematol.2019.237040.","DOI":"10.3324\/haematol.2019.237040"},{"key":"2320_CR18","doi-asserted-by":"publisher","unstructured":"Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A. 2010;107(1):407\u201312. https:\/\/doi.org\/10.1073\/pnas.0902006107.","DOI":"10.1073\/pnas.0902006107"},{"key":"2320_CR19","doi-asserted-by":"publisher","unstructured":"Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial. 2010;14(3):240\u201375. https:\/\/doi.org\/10.1111\/j.1744-9987.2010.00836.x.","DOI":"10.1111\/j.1744-9987.2010.00836.x"},{"issue":"24","key":"2320_CR20","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1002\/rcm.3319","volume":"21","author":"N Murao","year":"2007","unstructured":"Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography\/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom. 2007;21(24):4033\u20138. https:\/\/doi.org\/10.1002\/rcm.3319.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"2320_CR21","doi-asserted-by":"publisher","unstructured":"Ganz T, Jung G, Naeim A, Ginzburg Y, Pakbaz Z, Walter PB, et al. Immunoassay for human serum erythroferrone. Blood. 2017;130(10):1243\u20136. https:\/\/doi.org\/10.1182\/blood-2017-04-777987.","DOI":"10.1182\/blood-2017-04-777987"},{"key":"2320_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000496636","volume":"198","author":"T Nakanishi","year":"2019","unstructured":"Nakanishi T, Kimura T, Kuragano T. The Hepcidin-Anemia Axis: pathogenesis of Anemia in chronic kidney disease. Contrib Nephrol. 2019;198:124\u201334. https:\/\/doi.org\/10.1159\/000496636.","journal-title":"Contrib Nephrol"},{"issue":"7","key":"2320_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.bbamcr.2006.05.005","volume":"1763","author":"RS Ajioka","year":"2006","unstructured":"Ajioka RS, Phillips JD, Kushner JP. Biosynthesis of heme in mammals. Biochim Biophys Acta - Mol Cell Res. 2006;1763(7):723\u201336. https:\/\/doi.org\/10.1016\/j.bbamcr.2006.05.005.","journal-title":"Biochim Biophys Acta - Mol Cell Res"},{"issue":"15","key":"2320_CR24","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1046\/j.1432-1327.2000.01519.x","volume":"267","author":"S Taketani","year":"2000","unstructured":"Taketani S, Adachi Y, Nakahashi Y. Regulation of the expression of human ferrochelatase by intracellular iron levels. Eur J Biochem. 2000;267(15):4685\u201392. https:\/\/doi.org\/10.1046\/j.1432-1327.2000.01519.x.","journal-title":"Eur J Biochem"},{"issue":"3","key":"2320_CR25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2016.12.034","volume":"168","author":"MU Muckenthaler","year":"2017","unstructured":"Muckenthaler MU, Rivella S, Hentze MW, Galy B. A red carpet for Iron metabolism. Cell. 2017;168(3):344\u201361. https:\/\/doi.org\/10.1016\/j.cell.2016.12.034.","journal-title":"Cell."},{"key":"2320_CR26","doi-asserted-by":"publisher","unstructured":"Hanudel MR, Rappaport M, Gabayan V, Jung G, Salusky IB, Nemeth E, et al. Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model. Haematologica. 2017;102(3):e85\u20138. https:\/\/doi.org\/10.3324\/haematol.2016.150433.","DOI":"10.3324\/haematol.2016.150433"},{"issue":"MAR","key":"2320_CR27","first-page":"1","volume":"10","author":"AJ Van Vuren","year":"2019","unstructured":"Van Vuren AJ, Gaillard CAJM, Eisenga MF, Van Wijk R, Van Beers EJ. The EPO-FGF23 signaling pathway in erythroid progenitor cells: Opening a new area of research. Front Physiol. 2019;10(MAR):1\u201316.","journal-title":"Front Physiol"},{"issue":"8","key":"2320_CR28","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1182\/bloodadvances.2020001595","volume":"4","author":"AJ Van Vuren","year":"2020","unstructured":"Van Vuren AJ, Eisenga MF, Van Straaten S, Glenth\u00f8j A, Gaillard CAJM, Bakker SJL, et al. Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia. Blood Adv. 2020;4(8):1678\u201382. https:\/\/doi.org\/10.1182\/bloodadvances.2020001595.","journal-title":"Blood Adv"},{"key":"2320_CR29","doi-asserted-by":"publisher","unstructured":"Tanaka Y, Joki N, Hase H, Iwasaki M, Ikeda M, Ando R, et al. Effect of erythropoietin-stimulating agent on uremic inflammation. J Inflamm (Lond). 2012;9(1):17. https:\/\/doi.org\/10.1186\/1476-9255-9-17.","DOI":"10.1186\/1476-9255-9-17"},{"key":"2320_CR30","doi-asserted-by":"publisher","unstructured":"Liu WS, Chan HL, Lai YT, Yang YH, Teng HW, Liu CK, et al. Shift from darbepoetin-\u03b1 to continuous erythropoietin receptor activator decreases serum aluminium concentration in patients on hemodialysis. Environ Toxicol Pharmacol. 2016;45:108\u201314. https:\/\/doi.org\/10.1016\/j.etap.2016.05.021.","DOI":"10.1016\/j.etap.2016.05.021"},{"key":"2320_CR31","doi-asserted-by":"publisher","unstructured":"Sonnweber T, Theurl I, Seifert M, Schroll A, Eder S, Mayer G, et al. Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol Dial Transplant. 2011;26(3):977\u201387. https:\/\/doi.org\/10.1093\/ndt\/gfq483.","DOI":"10.1093\/ndt\/gfq483"},{"key":"2320_CR32","doi-asserted-by":"publisher","unstructured":"Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al. PIVOTAL investigators and committees. Intravenous Iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380(5):447\u201358. https:\/\/doi.org\/10.1056\/NEJMoa1810742.","DOI":"10.1056\/NEJMoa1810742"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02320-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-021-02320-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02320-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T10:03:35Z","timestamp":1617876215000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02320-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,8]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2320"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02320-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-143924\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,8]]},"assertion":[{"value":"9 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out according to the principles of the Declaration of Helsinki and approved by the ethics committee of Konan Medical Centre with an approval number of 26\u201303. Written informed consent to participate and for publication was obtained from each patient. This study was registered with the University Hospital Medical Information Network (ID UMIN000016552).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"T.N. reports personal fees from Kyowa-Kirin, personal fees from Chugai, personal fees from Torii Pharmaceuticals, personal fees from Bayer Yakuhin and personal fees from Tanabe-Mitsubishi, outside the submitted work. T.K. reports personal fees from Chugai, personal fees from Kyowa-Kirin, personal fees from Astellas, personal fees from Bayer Yakuhin, grants and personal fees from Ono, personal fees from Fuso, grants from Kissei and personal fees from Tanabe Mitsubishi, outside the submitted work. Other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}